

HIV

SURVEILLANCE DATA TABLES

Core Indicators for Monitoring the
Ending the HIV Epidemic Initiative
(*preliminary data*):

National HIV Surveillance System Data Reported
Through March 2024



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for HIV diagnoses reported to CDC through March 2024.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2024. *HIV Surveillance Data Tables* 2024;5(2). <https://www.cdc.gov/hiv-data/initiatives/#Current%20data%20releases>. Published July 2024. Accessed [date].

On the Web: <https://www.cdc.gov/hiv-data/initiatives/>

Confidential information, referrals, and educational material on HIV

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

This issue of *HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Taylor Jones, Juliet Morales, Anna Satcher Johnson, Zanetta Gant Sumner, Emily Zhu, Xueyuan Dong, Chan Jin, Xiaohong Hu, Jianmin Li, Stacy Cohen, and Michael Friend (editing and desktop publishing).

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	6
Tables	
1a Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2023 through March 2024—United States (preliminary)	7
1b Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2023 through March 2024—United States and 6 territories and freely associated states (preliminary)	8
1c Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2023 through March 2024—United States and 6 territories and freely associated states (preliminary)	9
1d Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2023 through March 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis during 2023 among persons aged ≥ 13 years, by selected characteristics—48 states and the District of Columbia (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis during 2023 among persons aged ≥ 13 years, by area of residence—48 states and the District of Columbia (preliminary)	13
2c Linkage to HIV medical care within 1 month of HIV diagnosis during 2023 among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	14
3 Ending the HIV Epidemic Phase I jurisdictions	16

Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases HIV Surveillance Data Tables on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core indicators for monitoring the Ending the HIV Epidemic initiative* report, available at <https://www.cdc.gov/hiv-data/initiatives/>.

The tables included in this report provide *preliminary* data on HIV diagnoses for the years 2023 and 2024 and linkage to HIV medical care for the year 2023 based on cases reported to CDC as of March 2024. Data for the 2 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. More information on HIV surveillance practices and limitations, demographic information, and geographic designations can be found in the Technical Notes of the *HIV Surveillance Report, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>.

TABULATION AND PRESENTATION OF DATA

HIV Diagnoses

HIV diagnoses are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2023 through March 2024 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2016–2020 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the years 2023 and 2024 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting HIV diagnoses can be found in the *HIV Surveillance Report, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years with HIV diagnosed during the year 2023 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years with HIV diagnosed during the year 2023 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed during the year 2023. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to the National HIV Surveillance System (NHSS); therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during the year 2023 and reported to NHSS

through March 2024. Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Data for Mississippi and West Virginia were included in analyses but should also be interpreted with caution due to a lapse in laboratory reporting that occurred during the year 2022.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-outcomes.html>.

References

1. HHS. EHE Overview. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated December 2023. Accessed June 26, 2024.

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2023 through March 2024—United States (preliminary)

	No. 2023	No. 2024 (January–March)
Gender		
Man	29,951	4,593
Woman	7,241	1,149
Transgender woman ^a	701	109
Transgender man ^a	62	6
Additional gender identity ^b	92	13
Age at diagnosis (yr)		
13–24	6,886	986
25–34	13,917	2,201
35–44	8,688	1,337
45–54	4,732	687
55–64	2,870	482
≥65	961	178
Race/ethnicity		
American Indian/Alaska Native	200	33
Asian	793	119
Black/African American	14,730	2,536
Hispanic/Latino ^c	12,394	1,739
Native Hawaiian/other Pacific Islander	62	18
White	9,009	1,354
Multiracial	866	72
Transmission category^d		
Male-to-male sexual contact ^e	25,347	3,879
Injection drug use ^f		
Male	1,343	186
Female	1,046	133
Male-to-male sexual contact ^e and injection drug use ^f	1,237	179
Heterosexual contact ^g		
Male	2,783	465
Female	6,210	1,015
Other ^h		
Male	34	5
Female	52	10
Region of residenceⁱ		
Northeast	5,070	672
Midwest	5,160	822
South	20,222	3,466
West	7,602	911
Total^j	38,054	5,871

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through March 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman.

“Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

ⁱ Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^j Includes persons of unknown gender.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2023 through March 2024—United States and 6 territories and freely associated states (preliminary)

	No. 2023	No. 2024 (January–March)
Gender		
Man	30,276	4,627
Woman	7,304	1,154
Transgender woman ^a	703	110
Transgender man ^a	62	6
Additional gender identity ^b	92	13
Age at diagnosis (yr)		
13–24	6,935	989
25–34	14,061	2,218
35–44	8,768	1,341
45–54	4,784	695
55–64	2,917	489
≥65	979	179
Race/ethnicity		
American Indian/Alaska Native	200	33
Asian	794	119
Black/African American	14,736	2,537
Hispanic/Latino ^c	12,762	1,774
Native Hawaiian/other Pacific Islander	62	19
White	9,023	1,357
Multiracial	867	72
Transmission category^d		
Male-to-male sexual contact ^e	25,598	3,902
Injection drug use ^f		
Male	1,357	189
Female	1,049	135
Male-to-male sexual contact ^e and injection drug use ^f	1,238	179
Heterosexual contact ^g		
Male	2,844	474
Female	6,270	1,017
Other ^h		
Male	35	5
Female	53	10
Region of residenceⁱ		
Northeast	5,070	672
Midwest	5,160	822
South	20,222	3,466
West	7,602	911
U.S. territories and freely associated states	390	40
Total^j	38,444	5,911

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau. Data are for cases reported to CDC through March 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

ⁱ Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^j Includes persons of unknown gender.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2023 through March 2024—United States and 6 territories and freely associated states (preliminary)

Area of residence	No.	No.
	2023	2024 (January–March)
Alabama	667	63
Alaska	25	4
Arizona	953	48
Arkansas	314	88
California	4,468	518
Colorado	477	82
Connecticut	243	31
Delaware	103	25
District of Columbia	193	11
Florida	4,675	1,154
Georgia	2,339	462
Hawaii	54	8
Idaho	49	0
Illinois	1,346	137
Indiana	671	107
Iowa	140	24
Kansas	146	21
Kentucky	389	41
Louisiana	875	159
Maine	35	13
Maryland	727	149
Massachusetts	454	19
Michigan	697	156
Minnesota	319	71
Mississippi	497	79
Missouri	551	74
Montana	24	4
Nebraska	99	14
Nevada	554	59
New Hampshire	35	6
New Jersey	929	81
New Mexico	121	4
New York	2,370	349
North Carolina	1,412	315
North Dakota	20	1
Ohio	863	167
Oklahoma	264	43
Oregon	243	35
Pennsylvania	933	155
Rhode Island	63	15
South Carolina	982	39
South Dakota	51	3
Tennessee	851	116
Texas	4,985	555
Utah	177	28
Vermont	8	3
Virginia	851	144
Washington	436	119
West Virginia	98	23
Wisconsin	257	47
Wyoming	21	2
Subtotal	38,054	5,871
U.S. territories and freely associated states		
American Samoa	0	0
Guam	3	1
Northern Mariana Islands	0	0
Puerto Rico	377	38
Republic of Palau	0	0
U.S. Virgin Islands	10	1
Subtotal	390	40
Total	38,444	5,911

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Numbers less than 12 should be interpreted with caution. Data are for cases reported to CDC through March 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2023 through March 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	No.	
	2023	2024 (January–March)
Arizona		
Maricopa County	629	23
California		
Alameda County	189	33
Los Angeles County	1,498	160
Orange County	259	43
Riverside County	294	33
Sacramento County	124	4
San Bernardino County	268	17
San Diego County	380	31
San Francisco County	180	39
District of Columbia	193	11
Florida		
Broward County	592	138
Duval County	269	60
Hillsborough County	366	80
Miami-Dade County	1,062	253
Orange County	493	128
Palm Beach County	282	83
Pinellas County	153	51
Georgia		
Cobb County	157	23
DeKalb County	297	59
Fulton County	440	105
Gwinnett County	223	35
Illinois		
Cook County	915	105
Indiana		
Marion County	260	40
Louisiana		
East Baton Rouge Parish	128	24
Orleans Parish	134	27
Maryland		
Baltimore City	166	30
Montgomery County	100	18
Prince George's County	196	42
Massachusetts		
Suffolk County	120	4
Michigan		
Wayne County	296	75
Nevada		
Clark County	494	49
New Jersey		
Essex County	194	18
Hudson County	111	8

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2023 through March 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	No.	No.
	2022 (<i>cont</i>)	2023 (January–March) (<i>cont</i>)
New York		
Bronx County	410	52
Kings County	476	85
New York County	304	46
Queens County	437	47
North Carolina		
Mecklenburg County	273	72
Ohio		
Cuyahoga County	151	28
Franklin County	210	33
Hamilton County	98	16
Pennsylvania		
Philadelphia County	376	75
Puerto Rico		
San Juan Municipio	93	10
Tennessee		
Shelby County	311	31
Texas		
Bexar County	362	43
Dallas County	821	149
Harris County	1,344	131
Tarrant County	344	37
Travis County	223	37
Washington		
King County	178	59
Total	17,873	2,800

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through March 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis during 2023 among persons aged ≥13 years, by selected characteristics—48 states and the District of Columbia (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Gender					
Man	29,158	24,402	83.7	4,756	16.3
Woman	7,071	5,809	82.2	1,262	17.8
Transgender woman ^a	688	606	88.1	82	11.9
Transgender man ^a	61	56	91.8	5	8.2
Additional gender identity ^b	91	83	91.2	8	8.8
Age at diagnosis (yr)					
13–24	6,732	5,547	82.4	1,185	17.6
25–34	13,556	11,354	83.8	2,202	16.2
35–44	8,459	7,050	83.3	1,409	16.7
45–54	4,593	3,871	84.3	722	15.7
55–64	2,797	2,350	84.0	447	16.0
≥65	939	789	84.0	150	16.0
Race/ethnicity					
American Indian/Alaska Native	196	165	84.2	31	15.8
Asian	776	670	86.3	106	13.7
Black/African American	14,417	11,641	80.7	2,776	19.3
Hispanic/Latino ^c	11,920	10,238	85.9	1,682	14.1
Native Hawaiian/other Pacific Islander	62	54	87.1	8	12.9
White	8,861	7,483	84.4	1,378	15.6
Multiracial	844	710	84.1	134	15.9
Transmission category^d					
Male-to-male sexual contact ^e	24,736	20,874	84.4	3,862	15.6
Injection drug use ^f	2,321	1,848	79.6	473	20.4
Male	1,289	1,016	78.8	273	21.2
Female	1,032	832	80.7	200	19.3
Male-to-male sexual contact ^e and injection drug use ^f	1,214	984	81.0	230	19.0
Heterosexual contact ^g	8,720	7,184	82.4	1,536	17.6
Male	2,666	2,189	82.1	476	17.9
Female	6,054	4,995	82.5	1,060	17.5
Total^h	37,076	30,961	83.5	6,115	16.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. Data are for cases reported to CDC through March 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^h Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis during 2023 among persons aged ≥13 years, by area of residence—48 states and the District of Columbia (preliminary)

Area of residence	Total diagnoses		≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	
Alabama	667	565	84.7	102	15.3	
Alaska	25	21	84.0	4	16.0	
Arizona	953	810	85.0	143	15.0	
Arkansas	314	272	86.6	42	13.4	
California	4,468	3,828	85.7	640	14.3	
Colorado	477	386	80.9	91	19.1	
Connecticut	243	201	82.7	42	17.3	
Delaware	103	85	82.5	18	17.5	
District of Columbia	193	163	84.5	30	15.5	
Florida	4,675	3,881	83.0	794	17.0	
Georgia	2,339	1,936	82.8	403	17.2	
Hawaii	54	46	85.2	8	14.8	
Illinois	1,346	1,146	85.1	200	14.9	
Indiana	671	523	77.9	148	22.1	
Iowa	140	130	92.9	10	7.1	
Kansas	146	119	81.5	27	18.5	
Kentucky	389	320	82.3	69	17.7	
Louisiana	875	722	82.5	153	17.5	
Maine	35	33	94.3	2	5.7	
Maryland	727	651	89.5	76	10.5	
Massachusetts	454	411	90.5	43	9.5	
Michigan	697	566	81.2	131	18.8	
Minnesota	319	292	91.5	27	8.5	
Mississippi ^a	497	384	77.3	113	22.7	
Missouri	551	461	83.7	90	16.3	
Montana	24	22	91.7	2	8.3	
Nebraska	99	86	86.9	13	13.1	
Nevada	554	460	83.0	94	17.0	
New Hampshire	35	27	77.1	8	22.9	
New Mexico	121	96	79.3	25	20.7	
New York	2,370	2,060	86.9	310	13.1	
North Carolina	1,412	1,122	79.5	290	20.5	
North Dakota	20	17	85.0	3	15.0	
Ohio	863	728	84.4	135	15.6	
Oklahoma	264	229	86.7	35	13.3	
Oregon	243	223	91.8	20	8.2	
Pennsylvania	933	793	85.0	140	15.0	
Rhode Island	63	57	90.5	6	9.5	
South Carolina	982	880	89.6	102	10.4	
South Dakota	51	44	86.3	7	13.7	
Tennessee	851	593	69.7	258	30.3	
Texas	4,985	4,030	80.8	955	19.2	
Utah	177	141	79.7	36	20.3	
Vermont	8	7	88.0	1	12.5	
Virginia	851	700	82.3	151	17.7	
Washington	436	378	86.7	58	13.3	
West Virginia ^a	98	65	66.3	33	33.7	
Wisconsin	257	231	89.9	26	10.1	
Wyoming	21	20	95.2	1	4.8	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after HIV diagnosis. Data are for cases reported to CDC through March 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

^a Data should be interpreted with caution due to a lapse in laboratory data completeness that occurred during the year 2022.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis during 2023 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Arizona					
Maricopa County	629	541	86.0	88	14.0
California					
Alameda County	189	166	87.8	23	12.2
Los Angeles County	1,498	1,281	85.5	217	14.5
Orange County	259	234	90.3	25	9.7
Riverside County	294	244	83.0	50	17.0
Sacramento County	124	109	87.9	15	12.1
San Bernardino County	268	197	73.5	71	26.5
San Diego County	380	333	87.6	47	12.4
San Francisco County	180	172	95.6	8	4.4
District of Columbia	193	163	84.5	30	15.5
Florida					
Broward County	592	475	80.2	117	19.8
Duval County	269	209	77.7	60	22.3
Hillsborough County	366	306	83.6	60	16.4
Miami-Dade County	1,062	876	82.5	186	17.5
Orange County	493	417	84.6	76	15.4
Palm Beach County	282	232	82.3	50	17.7
Pinellas County	153	122	79.7	31	20.3
Georgia					
Cobb County	157	134	85.4	23	14.6
DeKalb County	297	255	85.9	42	14.1
Fulton County	440	368	83.6	72	16.4
Gwinnett County	223	195	87.4	28	12.6
Illinois					
Cook County	915	784	85.7	131	14.3
Indiana					
Marion County	260	220	84.6	40	15.4
Louisiana					
East Baton Rouge Parish	128	104	81.3	24	18.8
Orleans Parish	134	110	82.1	24	17.9
Maryland					
Baltimore City	166	154	92.8	12	7.2
Montgomery County	100	88	88.0	12	12.0
Prince George's County	196	179	91.3	17	8.7
Massachusetts					
Suffolk County	120	111	92.5	9	7.5
Michigan					
Wayne County	296	229	77.4	67	22.6
Nevada					
Clark County	494	410	83.0	84	17.0
New York					
Bronx County	410	348	84.9	62	15.1
Kings County	476	391	82.1	85	17.9
New York County	304	254	83.6	50	16.4
Queens County	437	394	90.2	43	9.8

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis during 2023 among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
North Carolina					
Mecklenburg County	273	231	84.6	42	15.4
Ohio					
Cuyahoga County	151	133	88.1	18	11.9
Franklin County	210	184	87.6	26	12.4
Hamilton County	98	85	86.7	13	13.3
Pennsylvania					
Philadelphia County	376	322	85.6	54	14.4
Tennessee					
Shelby County	311	193	62.1	118	37.9
Texas					
Bexar County	362	291	80.4	71	19.6
Dallas County	821	650	79.2	171	20.8
Harris County	1,344	1,083	80.6	261	19.4
Tarrant County	344	284	82.6	60	17.4
Travis County	223	204	91.5	19	8.5
Washington					
King County	178	157	88.2	21	11.8
Total	17,475	14,622	83.7	2,853	16.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after HIV diagnosis. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through March 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

Table 3. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico^a	Alabama
Maricopa County	San Juan Municipio ^a	Arkansas
California		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey^a		
Essex County ^a		
Hudson County ^a		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 3. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

^a Linkage to care data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey and Puerto Rico.